827
Views
5
CrossRef citations to date
0
Altmetric
Hematological Malignancy

Mad2 overexpression is associated with high cell proliferation and reduced disease-free survival in primary gastrointestinal diffuse large B-cell lymphoma

, , , &

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Yiqun Huang, Yong Zou, Luhui Lin, Xudong Ma & Ruiji Zheng. (2019) miR-101 regulates cell proliferation and apoptosis by targeting KDM1A in diffuse large B cell lymphoma. Cancer Management and Research 11, pages 2739-2746.
Read now

Articles from other publishers (4)

Qinqiao Lai, Yan Zhao, Haiqing Yan & Hongling Peng. (2023) Advances in diagnosis, treatment and prognostic factors of gastrointestinal DLBCL. Leukemia Research 135, pages 107406.
Crossref
Zhengzi Qian, Leiyuan Chen, Xinyuan Wang, Yutian Kan, Yafei Wang, Yong Yu, Xiaofang Wang, Zhigang Zhao, Hongliang Yang, Peng Ge, Tingting Ding, Qiongli Zhai & Haifeng Zhao. (2021) Increased MALAT1 expression predicts poor prognosis in primary gastrointestinal diffuse large B-cell lymphoma. Clinical and Experimental Medicine 22:2, pages 183-191.
Crossref
Giorgia Simonetti, Samantha Bruno, Antonella Padella, Elena Tenti & Giovanni Martinelli. (2019) Aneuploidy: Cancer strength or vulnerability?. International Journal of Cancer 144:1, pages 8-25.
Crossref
Yang Lan, Xuewei Xiao, Zhengchi He, Yu Luo, Chuanfang Wu, Ling Li & Xu Song. (2018) Long noncoding RNA OCC-1 suppresses cell growth through destabilizing HuR protein in colorectal cancer. Nucleic Acids Research 46:11, pages 5809-5821.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.